Literature DB >> 11332680

Severe neonatal enteroviral hepatitis treated with pleconaril.

E Aradottir1, E M Alonso, S T Shulman.   

Abstract

Neonatal enteroviral hepatitis carries high morbidity and mortality. We treated three full term neonates with severe enteroviral hepatitis with pleconaril on an open label compassionate use protocol. Each mother had history of a viral-like syndrome within 1 week before delivery. The neonates presented at 4 to 5 days of age with fulminant hepatic failure with severe coagulopathy, and each yielded an echovirus. All were treated with pleconaril (VP63843) at 5 mg/kg every 8 h by nasogastric tube. Two of the three neonates with life-threatening enteroviral hepatitis recovered fully. Further experience with pleconaril for neonatal enteroviral hepatitis is warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11332680     DOI: 10.1097/00006454-200104000-00022

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  9 in total

Review 1.  Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.

Authors:  Anna Egorova; Sean Ekins; Michaela Schmidtke; Vadim Makarov
Journal:  Eur J Med Chem       Date:  2019-06-11       Impact factor: 6.514

2.  Nonpolio enterovirus infection in the neonate and young infant.

Authors:  Michael T Hawkes; Wendy Vaudry
Journal:  Paediatr Child Health       Date:  2005-09       Impact factor: 2.253

3.  A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis.

Authors:  Mark J Abzug; Marian G Michaels; Ellen Wald; Richard F Jacobs; José R Romero; Pablo J Sánchez; Gregory Wilson; Paul Krogstad; Gregory A Storch; Robert Lawrence; Mark Shelton; April Palmer; Joan Robinson; Penelope Dennehy; Sunil K Sood; Gretchen Cloud; Penelope Jester; Edward P Acosta; Richard Whitley; David Kimberlin
Journal:  J Pediatric Infect Dis Soc       Date:  2015-04-16       Impact factor: 3.164

Review 4.  Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus.

Authors:  Magloire Pandoua Nekoua; Enagnon Kazali Alidjinou; Didier Hober
Journal:  Nat Rev Endocrinol       Date:  2022-06-01       Impact factor: 47.564

Review 5.  Presentation, diagnosis, and management of enterovirus infections in neonates.

Authors:  Mark J Abzug
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

6.  Detection of echovirus 18 in human breast milk.

Authors:  Marcela V Maus; Michael A Posencheg; Kristin Geddes; Michael Elkan; Silvia Peñaranda; M Steven Oberste; Richard L Hodinka
Journal:  J Clin Microbiol       Date:  2008-01-16       Impact factor: 5.948

7.  Neonatal coxsackie B virus infection-a treatable disease?

Authors:  Penelope A Bryant; David Tingay; Peter A Dargaville; Mike Starr; Nigel Curtis
Journal:  Eur J Pediatr       Date:  2004-02-18       Impact factor: 3.183

8.  Clinical characteristics of severe neonatal enterovirus infection: a systematic review.

Authors:  Meng Zhang; Haoran Wang; Jun Tang; Yang He; Tao Xiong; Wenxing Li; Yi Qu; Dezhi Mu
Journal:  BMC Pediatr       Date:  2021-03-15       Impact factor: 2.125

9.  Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination.

Authors:  Nina Lindblom; Lars Lindquist; Jacob Westman; Mikael Åström; Roger Bullock; Suzanne Hendrix; Lars-Olof Wahlund
Journal:  J Alzheimers Dis Rep       Date:  2021-05-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.